SYSA1901 + trastuzumab + docetaxel

SYSA1901 + trastuzumab + docetaxel is an investigational combination regimen used intravenously, currently being evaluated for the treatment of HER2-positive breast cancer. SYSA1901’s mechanism and properties are not publicly disclosed, but it is being compared against established regimens such as pertuzumab plus trastuzumab and docetaxel in clinical trials. Trastuzumab is a monoclonal antibody targeting the HER2 protein, inhibiting HER2-mediated signaling and exerting immune-mediated cytotoxic effects. Docetaxel is a chemotherapeutic small molecule (taxane) that stabilizes microtubules and induces cell cycle arrest and apoptosis. This combination is investigated primarily for efficacy and safety in HER2-positive breast cancer[1].